Cargando…

Ethics and execution of developing a 2nd wave COVID vaccine – Our interim phase I/II VSV-SARS-CoV2 vaccine experience

Detalles Bibliográficos
Autores principales:	Levin, Yotam, Balakirski, Noa Madar, Caraco, Yoseph, Ben-Ami, Eytan, Atsmon, Jacob, Marcus, Hadar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043614/ https://www.ncbi.nlm.nih.gov/pubmed/33896663 http://dx.doi.org/10.1016/j.vaccine.2021.04.017

Ejemplares similares

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2022)

rVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits
por: Rosner, Amir, et al.
Publicado: (2022)

Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs
por: Madar-Balakirski, Noa, et al.
Publicado: (2022)

Titration methods for rVSV-based vaccine manufacturing
por: Gélinas, Jean-François, et al.
Publicado: (2020)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
por: Santoro, Francesco, et al.
Publicado: (2021)

Evaluation of a replication-competent VSV-SIV vaccine candidate
por: Jurgens, CK, et al.
Publicado: (2012)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Detectable Vesicular Stomatitis Virus (VSV)–Specific Humoral and Cellular Immune Responses Following VSV–Ebola Virus Vaccination in Humans
por: Poetsch, Joseph H, et al.
Publicado: (2019)

Optimization of single dose VSV-based COVID-19 vaccination in hamsters
por: O’Donnell, Kyle L., et al.
Publicado: (2021)

Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection
por: Menicucci, Andrea R., et al.
Publicado: (2019)

Spray dried VSV-vectored vaccine is thermally stable and immunologically active in vivo
por: Toniolo, Steven P., et al.
Publicado: (2020)

Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
por: Tober, R, et al.
Publicado: (2012)

Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
por: Wright, KJ, et al.
Publicado: (2012)

A VSV-based Zika virus vaccine protects mice from lethal challenge
por: Emanuel, Jackson, et al.
Publicado: (2018)

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Optimization of VSV‐ΔG‐spike production process with the Ambr15 system for a SARS‐COV‐2 vaccine
por: Rosen, Osnat, et al.
Publicado: (2022)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Upcoming IJTMB Initiatives from the Interim Executive Editor
por: Kennedy, Ann Blair
Publicado: (2016)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
por: Cross, Robert W., et al.
Publicado: (2020)

Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins
por: O’Donnell, Kyle L., et al.
Publicado: (2022)

Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates
por: Bhatia, Bharti, et al.
Publicado: (2023)

In-Line Monitoring of Downstream Purification Processes for VSV Based SARS-CoV-2 Vaccine Using a Novel Technique
por: Makovitzki, Arik, et al.
Publicado: (2021)

Highly Efficient Purification of Recombinant VSV-∆G-Spike Vaccine against SARS-CoV-2 by Flow-Through Chromatography
por: Lerer, Elad, et al.
Publicado: (2021)

Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation
por: Marzi, Andrea, et al.
Publicado: (2019)

Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine
por: Wong, Gary
Publicado: (2019)

Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge
por: Marzi, Andrea, et al.
Publicado: (2019)

Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease
por: Marzi, Andrea, et al.
Publicado: (2021)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
por: Cao, Wenguang, et al.
Publicado: (2023)

Ethical aspects of vaccines and vaccination
por: Spier, R.E.
Publicado: (1998)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Vaccination ethics
por: Giubilini, Alberto
Publicado: (2020)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
por: LeWitt, Peter A., et al.
Publicado: (2022)

Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
por: Makovitzki, Arik, et al.
Publicado: (2021)

Usp18 Expression in CD169(+) Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV
por: Friedrich, Sarah-Kim, et al.
Publicado: (2020)

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
por: Foster, Stephanie L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5m174sg7c76f35olf82u1sm833